Also trades as: LLY.TO (TSX) · $vol 2M · LLY.DE (XETRA) · $vol 2M · LLY.SW (SIX) · $vol 0M

$1,281.91

+2.77 (+0.22%)

After Hours: $1282.55 (+0.64, +0.05%)

Weekly Expected Move ±4.4%

$1162 $1218 $1273 $1329 $1385

NYSE · Healthcare · Drug Manufacturers - General · Tech Score Strong Buy · Power 82 · $1.20T mcap · 848M float · 0.308% daily turnover · Short 48% of daily vol

Credit Risk of going bust: lower than 84% of companies Debt: 4.4% of company value Bonds: $1.28B held by 465 funds, 44 bp over Treasuries → details ▾

Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $5.05 (down 99.6%), Eli Lilly and Company would be worth roughly what it owes.
Total debt $54.91B against a stock market value of $1.20T.
Distance to default 10.86 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $30.98B (short-term plus half of long-term), stock volatility 34.6%; Altman Z 8.56. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue

$65.2B +44.7% ▲

5Y CAGR: +21.6%

Gross Profit

$54.6B +49.1% ▲

5Y CAGR: +23.4%

Operating Income

$29.7B +69.7% ▲

5Y CAGR: +32.7%

Net Income

$20.6B +94.9% ▲

5Y CAGR: +27.2%

EPS (Diluted)

$22.95 +96.0% ▲

5Y CAGR: +28.8%

EBITDA

$27.9B +83.5% ▲

5Y CAGR: +25.7%

Profit Margins

Year-over-Year Growth

View Full Income Statement

Line Item	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$28.3B	$28.5B	$34.1B	$45.0B	$65.2B
YoY Growth	+15.4%	+0.8%	+19.6%	+32.0%	+44.7%
Cost of Revenue	$7.3B	$6.6B	$7.1B	$8.4B	$10.6B
Gross Profit	$21.0B	$21.9B	$27.0B	$36.6B	$54.6B
Gross Margin	74.2%	76.8%	79.2%	81.3%	83.8%
R&D Expenses	$6.9B	$7.2B	$9.3B	$11.0B	$13.3B
SG&A Expenses	$6.1B	$6.1B	$6.9B	$8.1B	$11.1B
Operating Expenses	$13.1B	$13.3B	$16.3B	$19.1B	$24.9B
Operating Income	$7.9B	$8.7B	$10.8B	$17.5B	$29.7B
Operating Margin	28.0%	30.3%	31.6%	38.9%	45.6%
Interest Expense	$340M	$332M	$486M	$781M	$795M
Income Before Tax	$6.2B	$6.8B	$6.6B	$12.7B	$25.7B
Tax Expense	$574M	$562M	$1.3B	$2.1B	$5.1B
Net Income	$5.6B	$6.2B	$5.2B	$10.6B	$20.6B
Net Margin	19.7%	21.9%	15.4%	23.5%	31.7%
EPS (Diluted)	$5.85	$6.57	$5.80	$11.71	$22.95
EBITDA	$8.0B	$8.7B	$8.6B	$15.2B	$27.9B
Shares Outstanding	954M	950M	903M	904M	898M

Line Item	FY2024 Q3	FY2024 Q4	FY2025 Q1	FY2025 Q2	FY2025 Q3	FY2025 Q4	FY2026 Q1	FY2026 Q2
Revenue	$11.4B	$13.5B	$12.7B	$15.6B	$17.6B	$19.3B	$19.8B	$23.0B
Cost of Revenue	$2.2B	$2.4B	$2.2B	$2.4B	$3.0B	$2.9B	$3.6B	$3.3B
Gross Profit	$9.3B	$11.1B	$10.5B	$13.1B	$14.6B	$16.4B	$16.2B	$19.7B
Gross Margin	81.0%	82.2%	82.5%	84.3%	82.9%	85.1%	81.9%	85.8%
R&D Expenses	$2.7B	$3.0B	$2.7B	$3.3B	$3.5B	$3.8B	$3.5B	$3.8B
SG&A Expenses	$2.0B	$2.3B	$2.4B	$2.6B	$2.7B	$3.3B	$2.9B	$3.4B
Operating Expenses	$4.7B	$5.3B	$5.1B	$6.0B	$6.2B	$7.6B	$6.4B	$7.2B
Operating Income	$4.5B	$5.8B	$5.4B	$7.1B	$8.4B	$8.8B	$9.8B	$12.5B
Operating Margin	39.8%	42.8%	42.5%	45.8%	47.6%	45.5%	49.4%	54.2%
Interest Expense	$193M	$225M	$244M	$249M	$180M	$123M	$332M	$345M
Income Before Tax	$1.6B	$5.0B	$3.5B	$6.8B	$7.2B	$8.3B	$8.8B	$9.2B
Tax Expense	$618M	$629M	$697M	$1.1B	$1.6B	$1.6B	$1.5B	$2.2B
Net Income	$970M	$4.4B	$2.8B	$5.7B	$5.6B	$6.6B	$7.4B	$7.1B
Net Margin	8.5%	32.6%	21.7%	36.4%	31.7%	34.4%	37.4%	30.9%
EPS (Diluted)	$1.07	$4.88	$3.06	$6.29	$6.21	$7.39	$8.26	$7.94
EBITDA	$2.2B	$5.7B	$4.2B	$7.5B	$7.9B	$8.4B	$10.3B	$13.0B
Shares Outstanding	905M	903M	901M	900M	899M	898M	896M	894M

LLY NYSE